Patents by Inventor Kevin Lewis Otipoby

Kevin Lewis Otipoby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VARIANT IgG FC POLYPEPTIDES AND USES THEREOF
    Publication number: 20250074984
    Abstract: Embodiments provided herein, provide for variant IgG Fc polypeptides, dimeric molecules, pharmaceutical compositions, and methods that can be used to target at cells to modulate the activity of the same to treat disorders, such as autoimmune disorders or cancers.
    Type: Application
    Filed: March 22, 2024
    Publication date: March 6, 2025
    Inventors: Yen-Lin Chen, Ryan Peckner, Nathan Higginson-Scott, Daniela Cipolletta, Yanfeng Zhou, Kevin Lewis Otipoby, Jyothsna Visweswaraiah
  • PROTEASE VARIANTS AND USES THEREOF
    Publication number: 20250027068
    Abstract: Embodiments provided herein, provide for polypeptides and molecules comprising a polypeptide having protease activity and a variant Fc molecule, pharmaceutical compositions comprising the same, and methods that can be used to treat disorders, such as IgG mediated disorders.
    Type: Application
    Filed: September 13, 2024
    Publication date: January 23, 2025
    Inventors: Nathan Higginson-Scott, Nathan Rollins, Jordan Anderson, Alex Pellerin, Ryan Peckner, Yi Xing, Ivan Mascanfroni, Kevin Lewis Otipoby, Yanfeng Zhou
  • TARGETED IMMUNOTOLERANCE WITH A PD-1 AGONIST
    Publication number: 20250002582
    Abstract: Methods and polypeptides for conferring site-specific or local immune privilege.
    Type: Application
    Filed: August 29, 2024
    Publication date: January 2, 2025
    Applicant: Pandion Operations, Inc.
    Inventors: Nathan Higginson-Scott, Joanne L. Viney, Kevin Lewis Otipoby, Salvatore Alioto, Lindsay J. Edwards, Jacob Glanville, David Maurer, Sarah Ives, Sawsan Youssef, Devanshi Shanghavi, Lauren Schwimmer
  • MOLECULES FOR MODULATING THE IMMUNE SYSTEM AND USES THEREOF
    Publication number: 20240368283
    Abstract: Embodiments provided herein, provide for polypeptides, pharmaceutical compositions, and methods that can be used, for example, to target at least two types of cells to modulate the activity of the same to treat disorders, such as autoimmune disorders or cancers.
    Type: Application
    Filed: April 26, 2024
    Publication date: November 7, 2024
    Inventors: Nathan Higginson-Scott, Daniela Cipolletta, Jyothsna Visweswaraiah, Rebecca Goydel, Andre Stanlie, Kevin Lewis Otipoby, Stephen R. Lutz, Michael P. Cianci, Yen-Lin Chen, Ryan Peckner, Yanfeng Zhou
  • Protease variants and uses thereof
    Patent number: 12129499
    Abstract: Embodiments provided herein, provide for polypeptides and molecules comprising a polypeptide having protease activity and a variant Fc molecule, pharmaceutical compositions comprising the same, and methods that can be used to treat disorders, such as IgG mediated disorders.
    Type: Grant
    Filed: January 5, 2024
    Date of Patent: October 29, 2024
    Assignee: Seismic Therapeutic, Inc.
    Inventors: Nathan Higginson-Scott, Nathan Rollins, Jordan Anderson, Alex Pellerin, Ryan Peckner, Yi Xing, Ivan Mascanfroni, Kevin Lewis Otipoby, Yanfeng Zhou
  • IL-2 MUTEINS AND USES THEREOF
    Publication number: 20240247039
    Abstract: The present application provides for IL-2 muteins, compositions comprising the same, and methods of using the same.
    Type: Application
    Filed: February 23, 2024
    Publication date: July 25, 2024
    Applicant: Pandion Operations, Inc.
    Inventors: Nathan Higginson-Scott, Joanne L. Viney, Jyothsna Visweswaraiah, Erik Robert Sampson, Kevin Lewis Otipoby
  • IL-2 MUTEINS AND USES THEREOF
    Publication number: 20240239858
    Abstract: The present application provides for IL-2 muteins, compositions comprising the same, and methods of using the same.
    Type: Application
    Filed: March 14, 2024
    Publication date: July 18, 2024
    Applicant: Pandion Operations, Inc.
    Inventors: Nathan Higginson-Scott, Joanne L. Viney, Jyothsna Visweswaraiah, Erik Robert Sampson, Kevin Lewis Otipoby
  • VARIANT IgG FC POLYPEPTIDES AND USES THEREOF
    Publication number: 20240228621
    Abstract: Embodiments provided herein, provide for variant IgG Fc polypeptides, dimeric molecules, pharmaceutical compositions, and methods that can be used to target at cells to modulate the activity of the same to treat disorders, such as autoimmune disorders or cancers.
    Type: Application
    Filed: October 25, 2023
    Publication date: July 11, 2024
    Inventors: Yen-Lin Chen, Ryan Peckner, Nathan Higginson-Scott, Daniela Cipolletta, Yanfeng Zhou, Kevin Lewis Otipoby, Jyothsna Visweswaraiah
  • PROTEASE VARIANTS AND USES THEREOF
    Publication number: 20240229002
    Abstract: Embodiments provided herein, provide for polypeptides and molecules comprising a polypeptide having protease activity and a variant Fc molecule, pharmaceutical compositions comprising the same, and methods that can be used to treat disorders, such as IgG mediated disorders.
    Type: Application
    Filed: January 5, 2024
    Publication date: July 11, 2024
    Inventors: Nathan Higginson-Scott, Nathan Rollins, Jordan Anderson, Alex Pellerin, Ryan Peckner, Yi Xing, Ivan Mascanfroni, Kevin Lewis Otipoby, Yanfeng Zhou
  • Variant IgG Fc polypeptides and uses thereof
    Patent number: 12030945
    Abstract: Embodiments provided herein, provide for variant IgG Fc polypeptides, dimeric molecules, pharmaceutical compositions, and methods that can be used to target at cells to modulate the activity of the same to treat disorders, such as autoimmune disorders or cancers.
    Type: Grant
    Filed: October 25, 2023
    Date of Patent: July 9, 2024
    Assignee: Seismic Therapeutic, Inc.
    Inventors: Yen-Lin Chen, Ryan Peckner, Nathan Higginson-Scott, Daniela Cipolletta, Yanfeng Zhou, Kevin Lewis Otipoby, Jyothsna Visweswaraiah
  • Tissue targeted immunotolerance with a CD39 effector
    Patent number: 11981715
    Abstract: Methods and compounds for conferring site-specific or local immune privilege, such as to the skin.
    Type: Grant
    Filed: February 18, 2021
    Date of Patent: May 14, 2024
    Assignee: Pandion Operations, Inc.
    Inventors: Daniel Rios, Purvi Mande, Joanne L. Viney, Nathan Higginson-Scott, Kevin Lewis Otipoby, Susmita Borthakur, Salvatore Alioto, Lindsay J. Edwards
  • VARIANT IgG FC POLYPEPTIDES AND USES THEREOF
    Publication number: 20240132592
    Abstract: Embodiments provided herein, provide for variant IgG Fc polypeptides, dimeric molecules, pharmaceutical compositions, and methods that can be used to target at cells to modulate the activity of the same to treat disorders, such as autoimmune disorders or cancers.
    Type: Application
    Filed: October 24, 2023
    Publication date: April 25, 2024
    Inventors: Yen-Lin Chen, Ryan Peckner, Nathan Higginson-Scott, Daniela Cipolletta, Yanfeng Zhou, Kevin Lewis Otipoby, Jyothsna Visweswaraiah
  • IL-2 muteins and uses thereof
    Patent number: 11965008
    Abstract: The present application provides for IL-2 muteins, compositions comprising the same, and methods of using the same.
    Type: Grant
    Filed: July 27, 2021
    Date of Patent: April 23, 2024
    Assignee: PANDION OPERATIONS, INC.
    Inventors: Nathan Higginson-Scott, Joanne L. Viney, Jyothsna Visweswaraiah, Erik Robert Sampson, Kevin Lewis Otipoby
  • IL-2 muteins and uses thereof
    Patent number: 11945852
    Abstract: The present application provides for IL-2 muteins, compositions comprising the same, and methods of using the same.
    Type: Grant
    Filed: July 26, 2021
    Date of Patent: April 2, 2024
    Assignee: PANDION OPERATIONS, INC.
    Inventors: Nathan Higginson-Scott, Joanne L. Viney, Jyothsna Visweswaraiah, Erik Robert Sampson, Kevin Lewis Otipoby
  • IL-2 muteins and uses thereof
    Patent number: 11779632
    Abstract: The present application provides for IL-2 muteins, compositions comprising the same, and methods of using the same.
    Type: Grant
    Filed: March 15, 2021
    Date of Patent: October 10, 2023
    Assignee: PANDION OPERATION, INC.
    Inventors: Nathan Higginson-Scott, Joanne L. Viney, Jyothsna Visweswaraiah, Erik Robert Sampson, Kevin Lewis Otipoby
  • MAdCAM targeted immunotolerance
    Patent number: 11739146
    Abstract: Methods and compounds for conferring site-specific or local immune privilege, such as targeting to a cell expressing MAdCAM.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: August 29, 2023
    Assignee: PANDION OPERATIONS, INC.
    Inventors: Nathan Higginson-Scott, Joanne L. Viney, Kevin Lewis Otipoby, Jyothsna Visweswaraiah, Salvatore Alioto, Lindsay J. Edwards, Erik Sampson, Jacob Glanville, David Maurer, Sarah Ives, Christina Pettus, Lauren Schwimmer
  • IL-2 MUTEINS AND USES THEREOF
    Publication number: 20220195003
    Abstract: The present application provides for IL-2 muteins, compositions comprising the same, and methods of using the same.
    Type: Application
    Filed: July 27, 2021
    Publication date: June 23, 2022
    Inventors: Nathan Higginson-Scott, Joanne L. Viney, Jyothsna Visweswaraiah, Erik Robert Sampson, Kevin Lewis Otipoby
  • IL-2 MUTEINS AND USES THEREOF
    Publication number: 20220185859
    Abstract: The present application provides for IL-2 muteins, compositions comprising the same, and methods of using the same.
    Type: Application
    Filed: July 26, 2021
    Publication date: June 16, 2022
    Inventors: Nathan Higginson-Scott, Joanne L. Viney, Jyothsna Visweswaraiah, Erik Robert Sampson, Kevin Lewis Otipoby
  • TARGETED IMMUNOTOLERANCE
    Publication number: 20220041713
    Abstract: Methods and compounds for conferring site-specific or local immune privilege.
    Type: Application
    Filed: September 18, 2019
    Publication date: February 10, 2022
    Inventors: Joanne L. Viney, Nathan Higginson-Scott, Micah Benson, Alan Crane, Kevin Lewis Otipoby
  • TISSUE TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
    Publication number: 20210269496
    Abstract: Methods and compounds for conferring site-specific or local immune privilege, such as to the skin.
    Type: Application
    Filed: February 18, 2021
    Publication date: September 2, 2021
    Inventors: Daniel Rios, Purvi Mande, Joanne L. Viney, Nathan Higginson-Scott, Kevin Lewis Otipoby, Susmita Borthakur, Salvatore Alioto, Lindsay J. Edwards